Anzeige
+++Erste Genehmigung für Tiefseebergbau seit 1980: Warum dieser Meilenstein für den nächsten Small-Cap-Akteur wichtig ist Warum dieser Meilenstein für den nächsten Small-Cap-Akteur wichtig ist+++
CLOVIS ONCOLOGY Forum: Community User: Maroni
Kommentare 2.548
V
VanHalen,
02.03.2016 23:50 Uhr
0
JPMorgan Chase & Co. reiterated their buy rating on shares of Clovis Oncology Inc (NASDAQ:CLVS)in a research note released on Friday morning,Analyst Ratings.Net reports. The brokerage currently has a $42.00 price objective on the biopharmaceutical company’s stock.
V
VanHalen,
02.03.2016 23:17 Uhr
0
Naja Bericht vom Montag.. Lächerlich xD
Die anderen Werten mit Buy und 40 USD
C
COLOGNE79,
02.03.2016 22:59 Uhr
0
Clovis Oncology Inc (NASDAQ:CLVS) had its price target decreased by Goldman Sachs from $23.00 to $19.00 in a report published on Monday,StockTargetPrices.com reports.
Shares of Clovis Oncology (NASDAQ:CLVS) opened at 18.00 on Monday. Clovis Oncology has a 12 month low of $17.17 and a 12 month high of $116.75. The firm’s market capitalization is $689.76 million. The stock has a 50 day moving average price of $22.47 and a 200 day moving average price of $60.48.
A number of hedge funds and institutional investors recently added to or reduced their stakes in CLVS. Vident Investment Advisory LLC boosted its position in Clovis Oncology by 55.2% in the fourth quarter. Vident Investment Advisory LLC now owns 42,347 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 15,062 shares in the last quarter. Credit Suisse AG boosted its position in Clovis Oncology by 19.3% in the fourth quarter. Credit Suisse AG now owns 125,000 shares of the biopharmaceutical company’s stock valued at $4,375,000 after buying an additional 20,219 shares in the last quarter. Redmile Group LLC boosted its position in Clovis Oncology by 87.5% in the fourth quarter. Redmile Group LLC now owns 1,795,936 shares of the biopharmaceutical company’s stock valued at $62,858,000 after buying an additional 838,302 shares in the last quarter. Palo Alto Investors LLC boosted its position in Clovis Oncology by 14.1% in the fourth quarter. Palo Alto Investors LLC now owns 3,547,719 shares of the biopharmaceutical company’s stock valued at $124,170,000 after buying an additional 438,911 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Clovis Oncology by 294.2% in the fourth quarter. Millennium Management LLC now owns 1,173,873 shares of the biopharmaceutical company’s stock valued at $41,086,000 after buying an additional 876,068 shares in the last quarter.
CLVS has been the subject of a number of other reports. Mizuho reduced their target price on shares of Clovis Oncology from $35.00 to $23.00 and set a neutral rating for the company in a research note on Monday, January 25th. JPMorgan Chase & Co. upped their target price on shares of Clovis Oncology from $103.00 to $110.00 and gave the stock an overweight rating in a research note on Friday, November 6th. Vetrraised shares of Clovis Oncology from a hold rating to a strong-buy rating and set a $54.87 target price for the company in a research note on Monday, November 16th. WallachBeth Capital lowered shares of Clovis Oncology from a buy rating to a hold rating and reduced their target price for the stock from $135.00 to $30.00 in a research note on Tuesday, November 17th. Finally,Zacks Investment Research lowered shares of Clovis Oncology from a hold rating to a sell rating in a research note on Friday, December 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $40.89.
Clovis Oncology, Inc (NASDAQ:CLVS) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib.
C
COLOGNE79,
02.03.2016 22:12 Uhr
0
sieht chartmässig auf jedem Fall gut aus auch wenn sie nochnal etwas zurückkommt
V
VanHalen,
02.03.2016 22:03 Uhr
0
Wenn die 19,7x gepackt werden ist der nächste technische Widerstand bei 21,6x.. Und dann BAM!
Xdiculator,
02.03.2016 21:54 Uhr
0
Es hat sich also gelohnt!
http://250kb.de/u/160302/j/rg2pRlILhsAm.jpg
V
VanHalen,
02.03.2016 21:30 Uhr
0
Oh mein Gott... Anschnallen!!
V
VanHalen,
02.03.2016 21:22 Uhr
0
Besser so :-P
C
COLOGNE79,
02.03.2016 20:41 Uhr
0
ich sag jetzt nix; )
V
VanHalen,
02.03.2016 20:36 Uhr
0
Auf und nieder.. Immer wieder....
C
COLOGNE79,
02.03.2016 20:26 Uhr
0
weiss ich doch:)
V
VanHalen,
02.03.2016 20:13 Uhr
0
War doch nur ironisch/Spaß ;-)
C
COLOGNE79,
02.03.2016 20:12 Uhr
0
ruhig Blut...wir haben getestet. ..nach einem Test kommt???....richtig. ..erneuter Versuch ...geduldig sein.Ssge ich immer und immer wieder gern
V
VanHalen,
02.03.2016 20:07 Uhr
0
Maaaan xD hättest nix gesacht Cologne
Xdiculator,
02.03.2016 20:01 Uhr
0
Mit Sicherheit! Nur wann?
C
COLOGNE79,
02.03.2016 19:58 Uhr
0
bald 40 usd? -;D
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | CLOVIS ONCOLOGY Hauptdiskussion | ||
| 2 | Clovis Oncology -Informationen Austausch |
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Critical Infrastructure Technologies Hauptdiskussion | -37,50 % | |
| 2 | Trading- und Aktien-Chat | ||
| 3 | Novo Nordisk nach Split | +3,66 % | |
| 4 | INTEL Hauptdiskussion | -1,06 % | |
| 5 | Freunde der Tellekom | +1,35 % | |
| 6 | für alle, die es ehrlich meinen beim Traden. | ||
| 7 | PLUG POWER Hauptdiskussion | ±0,00 % | |
| 8 | Beyond Meat Hauptdiskussion | +9,77 % | |
| 9 | Security der nächsten Generation | +8,64 % | |
| 10 | ROHÖL BRENT Hauptdiskussion | -0,50 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | Critical Infrastructure Technologies Hauptdiskussion | -37,50 % | |
| 2 | Novo Nordisk nach Split | +3,66 % | |
| 3 | INTEL Hauptdiskussion | -1,06 % | |
| 4 | Freunde der Tellekom | +1,35 % | |
| 5 | PLUG POWER Hauptdiskussion | ±0,00 % | |
| 6 | Beyond Meat Hauptdiskussion | +9,77 % | |
| 7 | Security der nächsten Generation | +8,64 % | |
| 8 | Haffner Energy SAS Hauptdiskussion | +18,48 % | |
| 9 | APPLE Hauptdiskussion | +3,45 % | |
| 10 | Canopy Hauptforum | +0,90 % | Alle Diskussionen |